TipRanks
Go Ultimate55% OFF

Basilea Pharmaceutica (0QNA) Share Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

0QNA Analyst Ratings

Moderate Buy
1Ratings
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to Basilea Pharmaceutica in the past 3 months

0QNA Stock 12 Month Forecast

CHF 110.00▲(55.15% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Basilea Pharmaceutica in the last 3 months. The average price target is CHF 110.00 with a high forecast of CHF 110.00 and a low forecast of CHF 110.00. The average price target represents a 55.15% change from the last price of CHF 70.90.
Highest Price TargetCHF 110.00Average Price TargetCHF 110.00Lowest Price TargetCHF 110.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for GB:0QNA
Analyst ProfileExpert FirmPrice TargetPositionUpside / DownsideActionDateFollowArticle
H.C. WainwrightCHF 105→CHF 110buy55.15%UpsideReiterated09/11/26
Kepler Capital CHF 69→CHF 70buy-1.27%DownsideReiterated04/13/26
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Basilea Pharmaceutica

3 Months
Ram Selvaraju
Ram SelvarajuH.C. Wainwright
Success Rate5/8 ratings generated profit
63%
Average Return
+3.59%

Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +3.59% per trade.

1 Year
Christophe dombu
Christophe dombuKepler Capital
Success Rate15/16 ratings generated profit
94%
Average Return
+23.93%

Copying Christophe dombu's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +23.93% per trade.

2 Years
Christophe dombu
Christophe dombuKepler Capital
Success Rate16/16 ratings generated profit
100%
Average Return
+44.82%

Copying Christophe dombu's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +44.82% per trade.

0QNA Analyst Recommendation Trends

02468Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
Monthly rating counts for 0QNA
RatingMay 26Jun 26Jul 26Aug 26Sep 26
Strong Buy00011
Buy20000
Hold00000
Sell00000
Strong Sell00000
total20011

In the current month, 0QNA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0QNA average Analyst price target in the past 3 months is 110.00.

0QNA Financial Forecast

CHF 0CHF 1.25CHF 2.5CHF 3.75CHF 5Q2 2025Q2 2026Q4 2026
HighCHF 3.28
ConsensusCHF 2.88
LowCHF 2.48

0QNA Earnings Forecast

Next quarter’s earnings estimate for 0QNA is CHF 2.88 with a range of CHF 2.48 to CHF 3.28. The previous quarter’s EPS was CHF 2.13. 0QNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year 0QNA has Performed in-line its overall industry.

CHF 104MCHF 116.5MCHF 129.1MCHF 141.7MCHF 154.3MQ2 2025Q2 2026Q4 2026
HighCHF 154M
ConsensusCHF 150M
LowCHF 148M

0QNA Sales Forecast

Next quarter’s sales forecast for 0QNA is CHF 150.33M with a range of CHF 148.30M to CHF 154.30M. The previous quarter’s sales results were CHF 119.00M. 0QNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year 0QNA has Performed in-line its overall industry.

0QNA Stock Forecast FAQ

What is GB:0QNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Basilea Pharmaceutica’s 12-month average price target is CHF110.00.
What is GB:0QNA’s upside potential, based on the analysts’ average price target?
Basilea Pharmaceutica has 55.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Basilea Pharmaceutica a Buy, Sell or Hold?
Basilea Pharmaceutica has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Basilea Pharmaceutica’s share price target?
The average share price target for Basilea Pharmaceutica is CHF110.00. This is based on 1 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF110.00, and the lowest forecast is CHF110.00. The average share price target represents a 55.15% increase from the current price of CHF70.9.
What do analysts say about Basilea Pharmaceutica?
Basilea Pharmaceutica’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of Basilea Pharmaceutica?
To buy shares of GB:0QNA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.